LISATA THERAPEUTICS, INC. annual report, FY2014

Filing identity and reporting period

Important discrepancy: The supplied filing identifies the registrant as Caladrius Biosciences, Inc., not Lisata Therapeutics, Inc. It is a Form 10-K for the fiscal year ended December 31, 2015, not a 2014 fourth-quarter filing. The summary below reflects the filing text provided.

Business context

Caladrius operated a cell-therapy development and manufacturing services business through PCT, alongside an early-stage therapeutic pipeline. PCT provided contract development, manufacturing, processing, and storage services. The lead internal candidate was CLBS03, a regulatory T-cell therapy in development for recent-onset type 1 diabetes.

Financial results and liquidity

• Revenue rose 25%, driven mainly by higher PCT clinical manufacturing services. Clinical services revenue increased 42%; processing and storage revenue increased 9%.
• Operating expenses were $136.3 million, including $62.3 million of goodwill and intangible-asset impairment. The impairment followed decisions to end CLBS10 development after its Phase 2 study and discontinue the CLBS20 Phase 3 melanoma study.
• Cash and cash equivalents were $20.3 million at year-end, versus $19.2 million; 2014 also included $7.1 million of marketable securities. Working capital was $8.3 million, and stockholders’ equity was $23.7 million.
• Long-term debt was $15.0 million at year-end, with $1.8 million of notes payable. The Oxford Finance loan carried an 8.5% rate and was due September 2018; scheduled future principal, interest, and fees were reported at $18.2 million.
• Caladrius raised $36.5 million net from common-stock issuance in 2015. Shares outstanding increased from 36.8 million at year-end 2014 to 56.7 million at year-end 2015.

Material changes, outlook, and risks

• Pipeline reset: CLBS10 was not to be pursued beyond the ongoing Phase 2 study; CLBS20’s Phase 3 monotherapy trial was discontinued amid changing melanoma competition. The related impairments and liability remeasurements materially affected reported results.
• CLBS03 outlook: Management expected to begin enrollment in the 111-patient Phase 2 T-Rex study in early 2016. The first 18 patients were to undergo an initial safety review after three-month follow-up, expected in early 2017, before possible enrollment of the remaining 93. These were forward-looking expectations, not completed milestones.
• Hitachi Chemical transaction, subsequent to year-end: In March 2016, Hitachi acquired a 19.9% interest in PCT for $19.4 million; a further $5.6 million in license-related payments was expected during 2016, with royalties on qualifying Asian contract revenue. Caladrius said it would receive $15 million of the equity proceeds and PCT would retain $4.4 million. A related Oxford amendment included a $7.0 million payment, extended interest-only payments to January 2017, and required specified future proceeds to be shared with the lender, subject to a $3.0 million cap and related minimum-payment terms.
• Management stated that year-end cash, operating revenue, the Hitachi transaction proceeds, and access to the Aspire Capital facility were expected to fund operations for the next 12 months. The company nevertheless said additional capital would be needed for longer-term needs and warned that unavailable or unfavorable financing could force delays or discontinuation of CLBS03 or business expansion.
• Other key risks include recurring losses and negative operating cash flow, dependence on external financing, customer and revenue concentration, clinical and regulatory uncertainty, manufacturing capacity and compliance requirements, and potential equity dilution. Four customers accounted for 49% of 2015 revenue and four customers represented 60% of year-end receivables.
• In February 2016, Nasdaq notified the company that its share price had remained below $1.00 for 30 consecutive trading days, creating a risk of delisting if compliance was not regained. The filing reported no legal proceedings expected to have a material effect. Auditors gave unqualified opinions on the financial statements and internal control over financial reporting.

Important facts for investors to verify

• Confirm the intended issuer and period: the supplied document is Caladrius Biosciences’ FY2015 10-K, not a Lisata Therapeutics FY2014 filing.
• Verify completion and cash receipt of the remaining Hitachi license payments, the allocation and use of transaction proceeds, and the resulting Oxford debt balance and proceeds-sharing obligations.
• Check whether the company’s stated 12-month liquidity outlook was achieved, including operating cash burn, Aspire facility availability, and any additional financing or dilution.
• Track CLBS03 enrollment, safety review, regulatory status, trial costs, and any changes to the stated study timetable.
• Review PCT revenue growth, margins, customer concentration, deferred process-development revenue, and capacity-expansion spending.
• Confirm subsequent Nasdaq listing status and the effect of outstanding options, warrants, and later share issuances on dilution.